Contraindicated (one)pentobarbital will minimize the level or influence of cariprazine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. CYP3A4 is chargeable for the development and elimination of cariprazine's Energetic metabolites.
pentobarbital will reduce the level or influence of alosetron by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unfamiliar.
pentobarbital increases toxicity of ifosfamide by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check. CYP3A4 inducers may possibly raise the metabolism of ifosfamide to its Energetic alkylating metabolites.
pentobarbital will lessen the extent or result of alosetron by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Unfamiliar.
Observe Carefully (one)pentobarbital will lessen the extent or influence of osilodrostat by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Contraindicated. Coadministration of doravirine with a strong CYP3A inducer may well decrease doravirine plasma concentrations and/or effects. Probable for lack of virologic reaction and possible resistance to doravirine.
pentobarbital will lower the level or outcome of elagolix by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
pentobarbital raises toxicity of methoxyflurane by expanding metabolism. Contraindicated. Improved metabolism of methoxyflurane to nephrotoxic compounds.
pentobarbital will lessen the level or influence of docetaxel by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Not known.
pentobarbital will decrease the extent or effect of fentanyl transmucosal by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Carefully. Coadministration of fentanyl with CYP3A4 inducers may lead to the lessen in fentanyl plasma concentrations, lack of efficacy or, quite possibly, advancement of a withdrawal syndrome in the affected person who has developed physical dependence to fentanyl.
Knowledge are now not accessible to Assess effect of barbiturates when forceps supply or other intervention is important; also, data will not be out there to ascertain the influence of such barbiturates over the later on progress, progress, and functional maturation of the kid
pentobarbital will lessen the extent or result of ambrisentan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Unfamiliar.
pentobarbital will decrease the level or impact of lefamulin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Steer clear of or Use Alternate Drug. Stay away from coadministration of lefamulin with robust or moderate CYP3A inducers unless the advantage outweighs pitfalls. Keep an eye on for diminished efficacy.
Contraindicated. Coadministration of lorlatinib with potent CYP3A check here inducers is contraindicated. Discontinue the solid CYP3A inducer for three plasma fifty percent-life prior to initiating lorlatinib.